Clinical Studies with In-111 BLEDTA, a Tumor-Imaging Conjugate of Bleomycin with a Bifunctional Chelating Agent

Indium-111 BLEDTA, a bleomycin analog containing an EDTA group, was used for tumor imaging in 110 patients with cancer. Scans with In-111 BLEDTA agreed with biopsy results in 75 of 95 patients (79% accuracy). A positive scan was obtained in 71 of 88 patients with a positive biopsy (81% sensitivity)....

Full description

Saved in:
Bibliographic Details
Published inThe Journal of nuclear medicine (1978) Vol. 22; no. 9; p. 787
Main Authors Goodwin, David A, Meares, Claude F, DeRiemer, Leslie H, Diamanti, Carol I, Goode, Richard L, Baumert, John E., Jr, Sartoris, David J, Lantieri, Robert L, Fawcett, H. Daniel
Format Journal Article
LanguageEnglish
Published United States Soc Nuclear Med 01.09.1981
Subjects
Adult
Aged
Background Radiation
Biopsy
Bleomycin
Carcinoma, Squamous Cell - diagnostic imaging
Chelating Agents
Edetic Acid - analogs & derivatives
False Negative Reactions
False Positive Reactions
Half-Life
Head and Neck Neoplasms - diagnostic imaging
Humans
Indium
Lung Neoplasms - diagnostic imaging
Male
Middle Aged
Radiation Dosage
Radioisotopes
Radionuclide Imaging
Online AccessGet full text

Cover

More Information
Summary:Indium-111 BLEDTA, a bleomycin analog containing an EDTA group, was used for tumor imaging in 110 patients with cancer. Scans with In-111 BLEDTA agreed with biopsy results in 75 of 95 patients (79% accuracy). A positive scan was obtained in 71 of 88 patients with a positive biopsy (81% sensitivity). In 21 of 95 patients (22%), the scan revealed tumor sites that had not been detected. The main limitation of visualization was the size of the tumor (1.5--2.0 cm diameter was the smallest size seen). Background radioactivity in the liver, spleen, and bone marrow also made tumor detection in these areas more difficult. The cause of this background, and of false-positive uptake in sites of inflammation, is correlated with specific radiolabeling of polymorphonuclear leukocytes by In-111 BLEDTA. Means of eliminating this background are discussed.
ISSN:0161-5505
1535-5667